Q3 Earnings Forecast for Immunocore Issued By HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Immunocore in a research note issued on Wednesday, August 12th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.08) for the quarter, up from their previous forecast of ($0.25). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for Immunocore’s Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at $0.11 EPS, Q1 2027 earnings at $0.18 EPS, Q2 2027 earnings at $0.29 EPS, FY2027 earnings at $1.36 EPS, FY2029 earnings at $7.70 EPS and FY2030 earnings at $10.87 EPS.

A number of other equities research analysts have also recently issued reports on the company. Morgan Stanley set a $43.00 target price on Immunocore in a research note on Friday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Mizuho lifted their target price on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Finally, Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and an average price target of $57.29.

Immunocore Stock Performance

Shares of IMCR stock opened at $34.20 on Friday. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94. The business has a 50 day moving average of $32.06 and a two-hundred day moving average of $31.32. The company has a market cap of $1.74 billion, a P/E ratio of -92.43 and a beta of 0.74. Immunocore has a 52 week low of $27.56 and a 52 week high of $40.71.

Immunocore (NASDAQ:IMCR) last released its earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%.The firm had revenue of $115.93 million for the quarter, compared to the consensus estimate of $148.57 million.

Institutional Investors Weigh In On Immunocore

A number of large investors have recently made changes to their positions in IMCR. Leonteq Securities AG purchased a new position in Immunocore during the 4th quarter worth approximately $30,000. Harbour Investments Inc. grew its stake in Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after acquiring an additional 388 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Immunocore in the fourth quarter worth approximately $47,000. Arax Advisory Partners grew its position in Immunocore by 302.9% during the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after purchasing an additional 1,042 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Immunocore by 202.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after buying an additional 1,286 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $0.11 from a prior estimate of ($0.45), a major improvement that implies Immunocore could become profitable sooner than previously expected.
• Positive Sentiment: The firm increased its Q3 2026 and Q4 2026 estimates to losses of ($0.08) and ($0.04), respectively, from prior forecasts of ($0.25) and ($0.20). The narrower projected losses point to improving operating performance.
• Positive Sentiment: Forecasts for 2027 were raised substantially: Q1 EPS increased to $0.18 from $0.07, Q2 to $0.29 from $0.17, and full-year EPS to $1.36 from $0.90.
• Positive Sentiment: Longer-term estimates also moved higher, with FY2028 EPS rising to $4.53, FY2029 to $7.70, and FY2030 to $10.87. These upgrades reinforce the analyst’s expectation for accelerating earnings growth.
• Positive Sentiment: HC Wainwright’s $100 target is well above Immunocore’s recent trading level near $34, potentially attracting investors focused on the company’s long-term commercial and earnings potential.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.